BACKGROUND: Chemotherapy-related amenorrhea is a frequent side effect observed in young breast cancer patients. Studies in mice revealed that chemotherapy-induced gonadal toxicity may result from vascular damage. We prospectively evaluated ovarian blood flow and function in young breast cancer patients following chemotherapy. METHODS: Young female patients with localized breast cancer undergoing adjuvant or neoadjuvant anthracycline- or taxane-based chemotherapy were evaluated using transvaginal ultrasound prior to initiation of and immediately after cessation of chemotherapy. Doppler-flow velocity indices of the ovarian vasculature-resistance index (RI), pulsatility index (PI)-and size measurements were visualized. Hormonal profiles, anti-Müllerian hormone (AMH) levels, and menopausal symptoms were assessed at the same time points. RESULTS: Twenty breast cancer patients were enrolled in the study. The median age was 34 ± 5.24 years. Ovarian blood flow was significantly reduced shortly following chemotherapy: RI decreased by 52.5% and PI decreased by 24.2%. The mean ovarian size declined by 19.08%. Patients who were treated with sequential chemotherapy experienced further reductions in ovarian blood flow and ovarian size after the second sequence. AMH levels dropped dramatically in all patients following treatment. Hormonal profiles after treatment depicted a postmenopausal profile for most patients, accompanied by related symptoms. CONCLUSIONS: Our results may imply a mechanism of chemotherapy-induced ovarian toxicity manifested by decreased ovarian blood flow accompanied by a reduction in ovarian size and diminished post-treatment AMH levels. Based upon our former preclinical studies, we assume that this may derive from an acute insult to the ovarian vasculature and may represent an initial event triggering a generalized phenomenon of end-organ toxicity.
BACKGROUND: Chemotherapy-related amenorrhea is a frequent side effect observed in young breast cancerpatients. Studies in mice revealed that chemotherapy-induced gonadal toxicity may result from vascular damage. We prospectively evaluated ovarian blood flow and function in young breast cancerpatients following chemotherapy. METHODS: Young female patients with localized breast cancer undergoing adjuvant or neoadjuvant anthracycline- or taxane-based chemotherapy were evaluated using transvaginal ultrasound prior to initiation of and immediately after cessation of chemotherapy. Doppler-flow velocity indices of the ovarian vasculature-resistance index (RI), pulsatility index (PI)-and size measurements were visualized. Hormonal profiles, anti-Müllerian hormone (AMH) levels, and menopausal symptoms were assessed at the same time points. RESULTS: Twenty breast cancerpatients were enrolled in the study. The median age was 34 ± 5.24 years. Ovarian blood flow was significantly reduced shortly following chemotherapy: RI decreased by 52.5% and PI decreased by 24.2%. The mean ovarian size declined by 19.08%. Patients who were treated with sequential chemotherapy experienced further reductions in ovarian blood flow and ovarian size after the second sequence. AMH levels dropped dramatically in all patients following treatment. Hormonal profiles after treatment depicted a postmenopausal profile for most patients, accompanied by related symptoms. CONCLUSIONS: Our results may imply a mechanism of chemotherapy-induced ovarian toxicity manifested by decreased ovarian blood flow accompanied by a reduction in ovarian size and diminished post-treatment AMH levels. Based upon our former preclinical studies, we assume that this may derive from an acute insult to the ovarian vasculature and may represent an initial event triggering a generalized phenomenon of end-organ toxicity.
Authors: L J King; S N Hasnain; J A Webb; J E Kingston; E A Shafford; T A Lister; J Shamash; R H Reznek Journal: Radiology Date: 1999-10 Impact factor: 11.105
Authors: Paniti Sukumvanich; L Doug Case; Kimberly Van Zee; S Eva Singletary; Electra D Paskett; Jeanne A Petrek; Elizabeth Naftalis; Michelle J Naughton Journal: Cancer Date: 2010-07-01 Impact factor: 6.860
Authors: Damon Duquaine; Glenn A Hirsch; Anjan Chakrabarti; Zhenguo Han; Chris Kehrer; Robert Brook; Joy Joseph; Anne Schott; B Kalyanaraman; Jeanette Vasquez-Vivar; Sanjay Rajagopalan Journal: Vasc Med Date: 2003-05 Impact factor: 3.239
Authors: Christien Weenen; Joop S E Laven; Anne R M Von Bergh; Mark Cranfield; Nigel P Groome; Jenny A Visser; Piet Kramer; Bart C J M Fauser; Axel P N Themmen Journal: Mol Hum Reprod Date: 2004-02 Impact factor: 4.025
Authors: Thomas W Kelsey; Phoebe Wright; Scott M Nelson; Richard A Anderson; W Hamish B Wallace Journal: PLoS One Date: 2011-07-15 Impact factor: 3.240
Authors: Irit Ben-Aharon; Tal Granot; Israel Meizner; Noa Hasky; Ana Tobar; Shulamith Rizel; Rinat Yerushalmi; Avi Ben-Haroush; Benjamin Fisch; Salomon M Stemmer Journal: Oncologist Date: 2015-06-22